Kelly McCaul, MD
Hematology & Oncology · Sioux Falls, SDNPI 1295701522
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,007,444 of the $1,237,267 with a category attached, or 81.4%. It is spread thinly across 37 manufacturers, the largest accounting for just 21.9%. Reporting peaked in 2019 at $253,460 and has fallen 63.9% since, to $91,414 in 2025. Among hematology & oncology clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,074 payments — averaging $1152.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$270K
- Karyopharm Therapeutics Inc.$243K
- Johnson & Johnson$146K
- E.r. Squibb & Sons, L.L.C.$133K
- Bristol Myers Squibb$128K
- Takeda Pharmaceuticals U.S.A., Inc.$90K
- plus $227K from 31 others
Across 80 payments — averaging $3386.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$173K
- Janssen Research & Development, LLC$40K
- Takeda Pharmaceuticals U.S.A., Inc.$29K
- Incyte Corporation$13K
- Amgen$9K
- Pharmacyclics LLC, An Abbvie Company$3K
- plus $5K from 3 others
What the payments were for
- Consulting fees$40,6293%
- Speaking & faculty fees$1,007,44481%
- Travel & lodging$169,64614%
- Food & beverage$19,1822%
- Education$3670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 259 | $270,473 |
| Karyopharm Therapeutics Inc. | 124 | $243,028 |
| Johnson & Johnson | 131 | $145,754 |
| E.r. Squibb & Sons, L.L.C. | 94 | $133,077 |
| Bristol Myers Squibb | 120 | $127,538 |
| Takeda Pharmaceuticals U.S.A., Inc. | 67 | $90,117 |
| Seagen Inc. | 75 | $76,453 |
| Amgen | 29 | $37,035 |
| AbbVie | 42 | $30,991 |
| Therakos LLC | 25 | $29,832 |
| Gilead | 19 | $14,182 |
| ADC Therapeutics America, Inc. | 12 | $10,103 |
| Agios Pharmaceuticals, Inc. | 16 | $8,389 |
| AstraZeneca(2 entities) | 10 | $7,924 |
| Mallinckrodt Hospital Products Inc. | 3 | $4,710 |
| Pfizer | 5 | $3,583 |
| Verastem, Inc. | 1 | $1,320 |
| Janssen Scientific Affairs, LLC | 1 | $1,090 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $713 |
| Daiichi Sankyo Inc. | 6 | $137 |
| Novartis | 4 | $116 |
| Genentech USA, Inc. | 4 | $96 |
| Jazz Pharmaceuticals Inc. | 2 | $92 |
| Merck | 3 | $90 |
| Sanofi | 3 | $76 |
| Beigene USA, Inc. | 3 | $70 |
| Astellas Pharma US Inc | 2 | $59 |
| Kyowa Kirin, Inc. | 2 | $40 |
| Sobi, Inc | 1 | $26 |
| Genentech, Inc. | 1 | $25 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| TG Therapeutics, Inc. | 1 | $18 |
| G1 Therapeutics, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,237,267 in reported general payments places this provider in the 95th percentile of 28 hematology & oncology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 21 | $266,970 |
| EliquisApixaban | 15 | $8,977 |
| Penicillin V Potassium | 12 | $197 |
| Acyclovir | 12 | $159 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $270,473 | $266,97021 claims |
| PfizerEliquis | $3,583 | $8,97715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 hematology & oncology providers in South Dakota.
Other hematology & oncology in Sioux Falls
- Roberto Ferro ValdesSioux Falls$142K
- Waqas JehangirSioux Falls$23K
- Steven PowellSioux Falls$13K
- Benjamin SolomonSioux Falls$5K
- Miroslaw MazurczakSioux Falls$2K
- Mark HuberSioux Falls$1K
- Ryan VacaSioux Falls$1K
- Michael McHaleSioux Falls$811
- Heidi McKeanSioux Falls$552
- Allison WatsonSioux Falls$254
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.